Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Petosemtamab plus mFOLFOX6 or FOLFIRI versus cetuximab plus mFOLFOX6 or FOLFIRI in first-line left-sided metastatic colorectal cancer
2026-525883-17-00Phase 3Authorised
- Sponsor
- Genmab
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of petosemtamab in colorectal cancer (CRC) (4 arms), sponsored by Genmab. Primary endpoints: Progression-free survival and Objective response rate. Planned start Oct 2026; status: authorised.
02
Drugs
petosemtamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2026-525883-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525883-17-00.